Drug delivery via the buccal mucosa offers a novel route of drug administration. The route has been tried for systemic delivery of a number of drug candidates since it overcomes first pass metabolism, gastrointestinal irritation and bioavailability and also for local delivery of drugs. Atenolol is an antihypertensive agent wildly used as a first line treatment for hypertension. It has half life 6-7 h. The drug is incompletely absorbing about 50 % but most of the absorbed drug reaches to the systemic circulation. Therefore it was planned in this investigation to develop controlled release mucoadhesive buccal tablets containing antihypertensive agent, atenolol to release the drug unidirectionallly in buccal cavity for extended periods of time for improvement in bioavailability, to reduce the dosing frequency and to improve the patient compliance. Also, it was planned to evaluate such mucoadhesive buccal tablets for their various pre-compression and compression characteristics, in vitro drug release kinetics and stability of the dosage forms.